Stock Performance and Market Context
On 02 Sep 2026, Shree Ganesh Biotech India Ltd recorded a day-on-day price drop of 2.00%, closing at Rs.0.49, which represents the lowest level ever reached by the stock. This decline outpaced the Sensex’s modest fall of 0.78% on the same day. Over the past week, the stock has fallen by 3.92%, compared to the Sensex’s 1.45% decline, while the one-month performance shows a sharper drop of 10.91% against the Sensex’s 2.24% fall.
Longer-term trends reveal a more pronounced underperformance. Over three months, the stock has declined by 19.67%, whereas the Sensex gained 2.27%. The one-year performance is particularly stark, with a 35.53% loss compared to the Sensex’s 4.75% decline. Year-to-date, the stock is down 20.97%, nearly double the Sensex’s 10.41% fall. Over three and five years, the stock has lost 51.00% and 92.92% respectively, while the Sensex has risen 16.76% and 31.97% over the same periods. The ten-year performance of the stock remains flat at 0.00%, contrasting sharply with the Sensex’s 167.58% gain.
Technical Indicators and Trading Patterns
The technical outlook for Shree Ganesh Biotech India Ltd remains bearish. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. The overall technical trend shifted to bearish on 16 Jun 2026 at a price of Rs.0.58, moving from a previously mildly bearish stance.
Key technical indicators such as the MACD and KST are bearish on a weekly basis, while monthly indicators show mild bearishness or no clear signals. Immediate support is identified at the current 52-week low of Rs.0.49, with resistance levels at Rs.0.52 (20-day moving average), Rs.0.58 (100-day moving average), and Rs.0.60 (200-day moving average). The 52-week high stands at Rs.0.80, representing a 38.75% distance from the current price.
Delivery volumes have shown some recent increase, with a 1-day delivery change of 26.57% compared to the 5-day average, and a 1-month delivery change of 9.2%. However, average monthly delivery volumes have declined slightly from 4.1 lakh shares in the previous month to 4.48 lakh shares in the trailing month.
Financial and Valuation Metrics
Shree Ganesh Biotech India Ltd is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector. The company’s valuation multiples reflect its current financial difficulties. The price-to-book value stands at a low 0.31x, indicating the stock is trading well below its book value. The enterprise value to EBITDA and EBIT ratios are negative at -6.90x, reflecting losses at the operating level. The EV to sales ratio is 2.42x, while EV to capital employed is 0.22x. The price-to-earnings ratio is not applicable due to the company’s loss-making status.
Dividend metrics are absent, with no dividend yield, payout, or ex-dividend dates reported, consistent with the company’s financial position.
Profitability and Earnings Trends
The company reported flat quarterly results for June 2026, with PBDIT and PBT less other income both at their lowest levels of Rs. -0.89 crore. Earnings per share for the quarter also hit a low of Rs. -0.01. The company’s EBITDA remains negative at Rs. -1.76 crore, underscoring ongoing profitability challenges.
Over the past year, profits have declined sharply by 86%, contributing to the stock’s 35.53% loss during the same period. The company’s return on equity averages a modest 2.62%, signalling limited profitability relative to shareholders’ funds. The EBIT to interest coverage ratio is weak at 0.35x, indicating constrained ability to service debt obligations.
Quality and Risk Assessment
Shree Ganesh Biotech India Ltd’s overall quality grade is below average, reflecting its long-term financial performance. Management risk and growth metrics are rated below average, while capital structure is considered good. The company maintains a net cash position, with negative net debt to equity of -0.12 and no promoter share pledging.
Sales and EBIT have contracted significantly over five years, with sales declining by 31.22% and EBIT by 204.98%. The company’s average return on capital employed is weak at 1.52%, and tax payments are negligible, with a tax ratio of zero. Institutional shareholding is low at 1.42%, with the majority of shares held by non-institutional investors.
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India Ltd’s performance contrasts with broader sector trends. The stock has underperformed its sector by 1.88% on the day of the all-time low and has consistently lagged behind the Sensex and sector averages over multiple time horizons. The company’s micro-cap status and financial metrics place it at a distinct disadvantage relative to larger, more stable peers.
Summary of Key Data Points
• All-time low price of Rs.0.49 reached on 02 Sep 2026
• Day change: -2.00%, underperforming Sensex (-0.78%) and sector (-1.88%)
• One-year return: -35.53% versus Sensex -4.75%
• Five-year return: -92.92% versus Sensex +31.97%
• Negative EBITDA of Rs. -1.76 crore
• PBDIT and PBT at lowest quarterly levels of Rs. -0.89 crore
• EPS at lowest quarterly level of Rs. -0.01
• Price-to-book ratio at 0.31x
• EBIT to interest coverage ratio at 0.35x
• Return on equity averaging 2.62%
• Below average quality grade with weak growth and management risk
• Majority shareholding by non-institutional investors
The stock’s current valuation and technical indicators reflect a continuation of the downward trend that has characterised Shree Ganesh Biotech India Ltd’s recent market performance. The all-time low price underscores the severity of the company’s financial and market position as of early September 2026.
